公开(公告)号：US20240343831A1

公开(公告)日：2024-10-17

申请号：US18642721

申请日：2024-04-22

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Alina BAUM ,  Christos KYRATSOUS ,  Lisa PURCELL

IPC: C07K16/40 ,  A61K39/395 ,  A61K45/06 ,  C12N9/50

CPC classification number: C07K16/40 ,  A61K39/3955 ,  A61K45/06 ,  C12N9/50 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/92

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to TMPRSS2 and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections or influenza virus infections).

公开(公告)号：US20240316169A1

公开(公告)日：2024-09-26

申请号：US18576623

申请日：2022-07-01

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Andrew J. Murphy ,  Christos KYRATSOUS ,  Alina BAUM ,  Christopher PETRO

IPC: A61K39/00 ,  A61K39/145 ,  A61K39/215 ,  A61K39/42 ,  A61P37/04

CPC classification number: A61K39/0008 ,  A61K39/145 ,  A61K39/215 ,  A61K39/42 ,  A61P37/04 ,  A61K2039/53 ,  A61K2039/545 ,  C12N2770/20023 ,  C12N2770/20052

Abstract: Described herein are methods and compositions for directing an antibody response in a subject away from one or more first epitopes of an antigen (e.g., immunodominant epitopes of a vaccine antigen) and towards one or more second epitopes of the antigen by administering one or more antibodies targeting the one or more first epitopes of the antigen.

公开(公告)号：US20240309072A1

公开(公告)日：2024-09-19

申请号：US18589384

申请日：2024-02-27

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Nianshuang WANG ,  Yang SHEN ,  Alina BAUM ,  Christos KYRATSOUS ,  Chia-Yang LIN

IPC: C07K16/10 ,  A61P31/14

CPC classification number: C07K16/1003 ,  A61P31/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/622

Abstract: The present disclosure provides multivalent anti-spike protein binding molecules, comprising multimerization moieties linked to anti-spike protein antigen-binding domains, that specifically bind to RBD regions of SARS-COV and/or SARS-COV-2. The present disclosure further relates to the methods of producing the multivalent anti-spike protein binding molecules, pharmaceutical compositions comprising of the multivalent anti-spike protein binding molecules, and methods of use of the multivalent anti-spike protein binding molecules to treat conditions associated with SARS-COV and SARS-COV-2 infections, such as COVID-19.

公开(公告)号：US20230125469A1

公开(公告)日：2023-04-27

申请号：US17863864

申请日：2022-07-13

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Alina BAUM ,  Christos KYRATSOUS ,  George D. YANCOPOULOS

IPC: C07K16/10 ,  C12N15/85 ,  C07K14/005 ,  A61K39/42 ,  A61P31/14

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

公开(公告)号：US20210246226A1

公开(公告)日：2021-08-12

申请号：US17171941

申请日：2021-02-09

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Alina BAUM ,  Christos KYRATSOUS ,  Lisa PURCELL

IPC: C07K16/40 ,  C12N9/50 ,  A61K39/395 ,  A61K45/06

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to TMPRSS2 and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections or influenza virus infections).

公开(公告)号：US20210171612A1

公开(公告)日：2021-06-10

申请号：US17082375

申请日：2020-10-28

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Alina BAUM ,  Christos KYRATSOUS

IPC: C07K16/10 ,  A61K45/06 ,  A61P31/16

Abstract: Provided herein are monoclonal antibodies, or antigen-binding fragments thereof, that bind to the influenza B hemagglutinin (HA) protein, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies are useful for inhibiting or neutralizing influenza B virus activity, thus providing a means of treating or preventing influenza infection in humans. Also provided is the use of one or more antibodies that bind to the influenza B HA for preventing viral attachment and/or entry into host cells. The antibodies may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.

公开(公告)号：US20240287162A1

公开(公告)日：2024-08-29

申请号：US18589364

申请日：2024-02-27

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Nianshuang WANG ,  Yang SHEN ,  Alina BAUM ,  Christos KYRATSOUS ,  Chia-Yang LIN ,  Tri NGUYEN

IPC: C07K16/10 ,  A61P31/14

CPC classification number: C07K16/1003 ,  A61P31/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35

Abstract: The present disclosure provides multivalent anti-spike protein binding molecules. The present disclosure further relates to the methods of producing the multivalent anti-spike protein binding molecules, pharmaceutical compositions comprising of the multivalent anti-spike protein binding molecules, and methods of use of the multivalent anti-spike protein binding molecules, e.g., to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.

公开(公告)号：US20240252601A1

公开(公告)日：2024-08-01

申请号：US18395175

申请日：2023-12-22

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Nianshuang WANG ,  Yang SHEN ,  Alina BAUM ,  Christos KYRATSOUS ,  Chia-Yang LIN

IPC: A61K38/48 ,  A61P31/14 ,  C12N9/48

CPC classification number: A61K38/48 ,  A61P31/14 ,  C12N9/485 ,  C12Y304/17023 ,  C07K2319/30

Abstract: The present disclosure provides ACE2 fusion proteins, comprising multimerization moieties linked to ACE2 moieties, that specifically bind to RBD regions of SARS-CoV and/or SARS-CoV-2. The present disclosure further relates to the methods of producing the ACE2 fusion proteins, pharmaceutical compositions comprising of the ACE2 fusion proteins, and methods of use of the ACE2 fusion proteins to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.

公开(公告)号：US20240100179A1

公开(公告)日：2024-03-28

申请号：US18225567

申请日：2023-07-24

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Alina BAUM ,  Thomas NITTOLI

IPC: A61K47/68 ,  A61K31/506 ,  A61K31/5383

CPC classification number: A61K47/6841 ,  A61K31/506 ,  A61K31/5383 ,  A61K47/6803

Abstract: Provided herein are compounds, compositions, and methods for the treatment of diseases and disorders associated with influenza, including VX-787 and derivatives thereof, baloxavir and derivatives thereof, and baloxavir marboxil and derivatives thereof, and protein (e.g., antibody) drug conjugates thereof.

公开(公告)号：US20230348569A1

公开(公告)日：2023-11-02

申请号：US18216118

申请日：2023-06-29

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Robert BABB ,  Alina BAUM ,  Gang CHEN ,  Cindy GERSON ,  Johanna HANSEN ,  Tammy HUANG ,  Christos KYRATSOUS ,  Wen-Yi LEE ,  Marine MALBEC ,  Andrew MURPHY ,  William OLSON ,  Neil STAHL ,  George D. YANCOPOULOS

IPC: C07K16/10 ,  A61K45/06 ,  A61K39/395 ,  A61K39/15

CPC classification number: C07K16/10 ,  A61K45/06 ,  A61K39/395 ,  A61K39/15 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/565

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).